Preserving Male Fertility After Cancer Therapy

癌症治疗后保持男性生育能力

基本信息

  • 批准号:
    9109653
  • 负责人:
  • 金额:
    $ 133.93万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2014
  • 资助国家:
    美国
  • 起止时间:
    2014-07-01 至 2019-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Chemotherapy and radiation treatments for cancer or other conditions can cause prolonged or permanent infertility. This is a significant human health concern because over 75,000 people under the age of 40 In the United States are diagnosed with cancer each year and most are cured. Adult men have the option to cryopreserve semen with sperm prior to gonadotoxic. This option is not available to prepubertal boys or adult male survivors who did not save a semen sample before treatment. For these patients, there are several stem cell technologies in the research pipeline that may preserve or restore fertility. Thi program project will generate pre-clinical radiation- and chemotherapy-induced models of male infertility in rhesus macaques that are relevant to human testis anatomy, physiology and pubertal development. The overall objective is to examine the long-term impacts of pre-pubertal chemotherapy and radiation exposure on stem cells and spermatogenesis and determine the potential of stem cell therapies to preserve and/or restore fertility. Proiect I (OnA/ig) will evalate the potential of spermatogonia stem cell (SSC) transplantation and testicular tissue grafting or organ culture to regenerate spermatogenesis and/or produce functional sperm in monkeys treated with gonadotoxic agents during childhood. Proiect II (Clark/Byrne) will derive animal-specific induced pluripotent stem cells (IPSCs) and differentiate them into transplantable germline stem cells with autologous transplantation into chemo- and radiation-treated recipients. Proiect III (Meistrich/Shettv) will develop novel hormone suppression strategies to stimulate spermatogenesis from endogenous and/or transplanted SSCs after exposure to gonadotoxic agents. The Administrative Core A will coordinate communication and collegial interaction between project sites, transfer of biological specimens and data and report progress to NIH. Transplant Core B will provide high quality disease free rhesus macaques of the appropriate ages, generate irradiated and chemotherapy-treated models of male infertility and provide the expertise for germ cell transplantation into mice and monkeys. Each project site brings unique knowledge, expertise and resources to the program that are not available in composite at any ofthe individual sites or anywhere else in the country. Collectively, the project leaders will generate a substantial body of pre-clinical data on the feasibility of stem cell-based methods for preserving and/or restoring fertility of patients receiving gonadotoxic therapies.
描述(由申请人提供):癌症或其他疾病的化疗和放射治疗可能导致长期或永久性不孕。这是一个重大的人类健康问题,因为在美国,每年有超过75,000名40岁以下的人被诊断患有癌症,大多数人被治愈。成年男性可以选择在发生性腺毒性之前冷冻精液和精子。这种选择不适用于青春期前的男孩或成年男性幸存者谁没有保存精液样本前治疗。对于这些患者,研究管道中有几种干细胞技术可以保留或恢复生育能力。该项目将产生临床前放射和化疗诱导的恒河猴雄性不育模型,与人类睾丸解剖学,生理学和青春期发育有关。总体目标是研究青春期前化疗和辐射暴露对干细胞和精子发生的长期影响,并确定干细胞治疗保留和/或恢复生育能力的潜力。项目I(OnA/IG)将评估精原细胞干细胞(SSC)移植和睾丸组织移植或器官培养在儿童期接受性腺毒性药物治疗的猴中再生精子发生和/或产生功能性精子的潜力。Proiect II(Clark/Byrne)将衍生动物特异性诱导多能干细胞(IPSC),并将其分化为可移植的生殖系干细胞,自体移植到化疗和放射治疗的受体中。项目III(Meistrich/Shettv)将开发新的激素抑制策略,以刺激暴露于性腺毒性剂后内源性和/或移植的SSC的精子发生。行政核心A将协调项目地点之间的沟通和学院互动,生物标本和数据的转移,并向NIH报告进展情况。移植核心B将提供高质量的无病恒河猴的适当年龄,产生辐射和化疗治疗的男性不育模型,并提供生殖细胞移植到小鼠和猴子的专业知识。每个项目现场带来独特的知识,专业知识和资源的计划,是没有在任何的个别网站或在该国其他任何地方的组合。总的来说,项目负责人将产生大量的临床前数据,这些数据是关于基于干细胞的方法用于保持和/或恢复接受性腺毒性治疗的患者的生育能力的可行性。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Kyle Edwin Orwig其他文献

Kyle Edwin Orwig的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Kyle Edwin Orwig', 18)}}的其他基金

Genetics of Male Infertility: A Marker of Overall Health
男性不育的遗传学:整体健康的标志
  • 批准号:
    10613339
  • 财政年份:
    2019
  • 资助金额:
    $ 133.93万
  • 项目类别:
Gene Therapy for Male Infertility
男性不育症的基因治疗
  • 批准号:
    10379350
  • 财政年份:
    2019
  • 资助金额:
    $ 133.93万
  • 项目类别:
Genetics of Male Infertility: A Marker of Overall Health
男性不育的遗传学:整体健康的标志
  • 批准号:
    10005443
  • 财政年份:
    2019
  • 资助金额:
    $ 133.93万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10613340
  • 财政年份:
    2019
  • 资助金额:
    $ 133.93万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10379347
  • 财政年份:
    2019
  • 资助金额:
    $ 133.93万
  • 项目类别:
Genetics of Male Infertility: A Marker of Overall Health
男性不育的遗传学:整体健康的标志
  • 批准号:
    10379346
  • 财政年份:
    2019
  • 资助金额:
    $ 133.93万
  • 项目类别:
Gene Therapy for Male Infertility
男性不育症的基因治疗
  • 批准号:
    10613346
  • 财政年份:
    2019
  • 资助金额:
    $ 133.93万
  • 项目类别:
Reproductive Development from Gonads to Fetuses
从性腺到胎儿的生殖发育
  • 批准号:
    9275659
  • 财政年份:
    2017
  • 资助金额:
    $ 133.93万
  • 项目类别:
Reproductive Development from Gonads to Fetuses
从性腺到胎儿的生殖发育
  • 批准号:
    10163223
  • 财政年份:
    2017
  • 资助金额:
    $ 133.93万
  • 项目类别:
Cellular Mechanisms of Chemotherapy-induced Male Infertility: Stem Cell or Niche?
化疗引起男性不育的细胞机制:干细胞还是利基?
  • 批准号:
    8636803
  • 财政年份:
    2014
  • 资助金额:
    $ 133.93万
  • 项目类别:

相似海外基金

Investigating the Adoption, Actual Usage, and Outcomes of Enterprise Collaboration Systems in Remote Work Settings.
调查远程工作环境中企业协作系统的采用、实际使用和结果。
  • 批准号:
    24K16436
  • 财政年份:
    2024
  • 资助金额:
    $ 133.93万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
WELL-CALF: optimising accuracy for commercial adoption
WELL-CALF:优化商业采用的准确性
  • 批准号:
    10093543
  • 财政年份:
    2024
  • 资助金额:
    $ 133.93万
  • 项目类别:
    Collaborative R&D
Unraveling the Dynamics of International Accounting: Exploring the Impact of IFRS Adoption on Firms' Financial Reporting and Business Strategies
揭示国际会计的动态:探索采用 IFRS 对公司财务报告和业务战略的影响
  • 批准号:
    24K16488
  • 财政年份:
    2024
  • 资助金额:
    $ 133.93万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 133.93万
  • 项目类别:
    EU-Funded
Assessing the Coordination of Electric Vehicle Adoption on Urban Energy Transition: A Geospatial Machine Learning Framework
评估电动汽车采用对城市能源转型的协调:地理空间机器学习框架
  • 批准号:
    24K20973
  • 财政年份:
    2024
  • 资助金额:
    $ 133.93万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 133.93万
  • 项目类别:
    EU-Funded
De-Adoption Beta-Blockers in patients with stable ischemic heart disease without REduced LV ejection fraction, ongoing Ischemia, or Arrhythmias: a randomized Trial with blinded Endpoints (ABbreviate)
在没有左心室射血分数降低、持续性缺血或心律失常的稳定型缺血性心脏病患者中停用β受体阻滞剂:一项盲法终点随机试验(ABbreviate)
  • 批准号:
    481560
  • 财政年份:
    2023
  • 资助金额:
    $ 133.93万
  • 项目类别:
    Operating Grants
Our focus for this project is accelerating the development and adoption of resource efficient solutions like fashion rental through technological advancement, addressing longer in use and reuse
我们该项目的重点是通过技术进步加快时装租赁等资源高效解决方案的开发和采用,解决更长的使用和重复使用问题
  • 批准号:
    10075502
  • 财政年份:
    2023
  • 资助金额:
    $ 133.93万
  • 项目类别:
    Grant for R&D
Engage2innovate – Enhancing security solution design, adoption and impact through effective engagement and social innovation (E2i)
Engage2innovate — 通过有效参与和社会创新增强安全解决方案的设计、采用和影响 (E2i)
  • 批准号:
    10089082
  • 财政年份:
    2023
  • 资助金额:
    $ 133.93万
  • 项目类别:
    EU-Funded
Collaborative Research: SCIPE: CyberInfrastructure Professionals InnoVating and brOadening the adoption of advanced Technologies (CI PIVOT)
合作研究:SCIPE:网络基础设施专业人员创新和扩大先进技术的采用 (CI PIVOT)
  • 批准号:
    2321091
  • 财政年份:
    2023
  • 资助金额:
    $ 133.93万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了